The United States will pay $ 1.95 billion to Pfizer and BioNTech, for a possible Covid-19 vaccine, if it would be safe and effective
The US could buy 100 million doses Covid-19 vaccine for $ 1.95 billion from Pfizer and BioNTech, to develop and ship, if it would be safe and effective for humans, as reported companies today. This deal is the largest between the state and the company. German company BioNTech and Pfizer are jointly developing four potential vaccines. So far, no data available, when the first trials will be launched, although companies previously reported that they could launch a medical trial that includes 30,000 participants if they get regulatory approval later this month, as reported CNBC.
The government also announced $ 456 million for vaccine candidate Johnson & Johnson in March, $ 486 million in support for the Moderna vaccine in April, and up to $ 1.2 billion in May for the AstraZeneca vaccine. The U.S. government has also allocated $ 628 million to Emergent Biosolutions to expand domestic manufacturing capacity to develop a potential coronavirus vaccine and drugs for the treatment of Covid-19.
Pfizer was up 3.8% in early trading on Wednesday, while BioNTech was up 4%. They were also followed by shares of other large companies, in the hope of positive results and an improvement in the situation with the pandemic.